Status:
UNKNOWN
Lactobacillus Helveticus in the Treatment of Major Depression
Lead Sponsor:
Federal University of Minas Gerais
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The main objective of the study is to evaluate whether the association of the probiotic Lactobacillus helveticus to standard antidepressant will contribute to the treatment of major depression.
Detailed Description
Patients with the diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria will receive one daily oral dose of 1 × 10\^9 colony-forming uni...
Eligibility Criteria
Inclusion
- Aged between 18 and 65 years old;
- Diagnosis of major depression
- Agree to sign the informed consent.
Exclusion
- Treatment with anti-inflammatory drugs or antibiotics of any pharmacological classes in the month before treatment enrollment;
- Use of dietary supplementation (herbal supplements, other pro- or prebiotics).
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04333277
Start Date
April 1 2020
End Date
April 1 2021
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clínicas
Belo Horizonte, Minas Gerais, Brazil, 30130-100